

References

References

- *Aaronson, S.A. (1991):*
Growth factors and cancer.
Science, 254: 1146.
- *Abelev, G.I.; Perov, S.D. and Khramkova, N.I. (1963):*
Production of embryonal α -globulin by transplantable mouse
hepatomas.
Transplantation, 1: 174.
- *Angerwall, L.; Bengtsson, U. and Zetterlud, C.G. (1969):*
Renal pelvic carcinoma in Swedish district with abuse of a
phenacetin containing drug.
Brit. J. Urol., 41: 401.
- *Armitage, N.C.; Perkines, A.C. and Hardcastle, J.D. (1984):*
The localization of an anti-tumor monoclonal antibody in
gastrointestinal tumors.
Brit. J. Surg., 71(6): 407.
- *Ashley, D.J. (1990):*
Tumors of the urinary tract.
In: Evan's Histological Appearances of Tumors, 4th_aEd.
Churchill Livingstone, Edinburgh, London, p. 921.

- ***Atack, D.B.; Nisker, J.A. and Levin, L. (1986):***
C.A. 125 surveillance and second-look laparotomy in ovarian carcinoma.
Am. J. Obst. Gynecol., 154: 287.

- ***Ayala, A.(1989):***
Premalignant lesions of the urothelium and transitional cell tumors.
In: Pathology of the Urinary Bladder, Ed. Young, R.H., Churchill Livingstone, New York, London, p. 226.

- ***Badalment, R.A.; Hermansen, D.K.; Kimmel, M., Gay, H.; Herr,H.W.; Fair, W.R.; Whitemore, W.F. and Melamed, M.R. (1987):***
The sensitivity of bladder wash flow cytometry, bladder wash cytology and voided cytology in the detection of bladder carcinoma.
Cancer, 60: 1423.

- ***Badr, M.M. and Torkey, A.H. (1966):***
Bilharzial bladder neck obstruction.
A review med. J. Cairo Univ., 34: 141.

- ***Banarjee, S. and Toole, B.P. (1992):***
Hyaluronan binding protein in endothelial cell morphogenesis.
J. Cell Biol., 119: 643.

- **Bastacky, S.; Ibrahim, S. and Wilezynski, S.P. (1999):**
The accuracy of urinary cytology in daily practice.
Cancer, 87: 118.
- **Bates, S.E. and Long, L.D. (1985):**
Tumor markers: Value and limitation in the management of
cancer patients.
Cancer Treat. Rev., 12: 163.
- **Berezney, R. (1979):**
In: The Cell Nucleus, Ed., Busch, H., Academic Press Inc.,
New York, 7: 413.
- **Berezney, R. (1984):**
In: Chromosomal Nonhistone Proteins, Ed., Hnilica, L.S.,
Boca Raton: C.R.C. Press, 4: 119.
- **Berezney, R. (1991):**
The nuclear matrix: a heuristic model for investigating
genomic organization and function in the cell nucleus.
J. Cell. Biochem., 47: 109.
- **Berezney, R. and Coffey, D.S. (1974):**
Identification of a nuclear protein matrix.
Biochem. Biophys. Res. Comm., 60: 1410.

-
- ***Bhattacharya, M. and Barlow, J.J. (1973a):***
Immunologic studies of human serous cystadenocarcinoma of ovary.
Cancer, 31: 588.
 - ***Bhattachaya, M. and Barlow, J.J. (1973b):***
Tumor markers: Value and limitations in management of cancer patients.
Cancer Treat. Rev., 12: 163.
 - ***Bidwell, J.P.; Fey, E.G.; Van Wijnen, A.J.; Penman, S.; Stein, J.L.; Lian, J.B. and Stein, G.S. (1994):***
Nuclear matrix proteins distinguish normal diploid osteoblasts from osteosarcoma cells.
Cancer Res., 54: 28.
 - ***Birkmayer, G.D. and Klavius, J.V. (1990):***
Classification of tumor markers.
The Second International Conference of the Egyptian Society of Tumor Markers Oncology (ESTMO) [Meeting Abstract], p. 46.
 - ***Blackburn, G.M. and Gait, M.J. (Eds.) (1990):***
Nucleic Acids in Chemistry and Biology, Oxford, IRL Press, p. 21.
-

- ***Bombardieri, E.E.; Gion, M. and Mione, R. (1989):***
A mucinous like carcinoma associated antigens (MCA) in
the tissue and blood of patients with cancer.
Cancer, 63: 490.
- ***Boring, C.C.; Squires, T.S.; Tong, T. and Montgomery, S. (1994):***
Cancer statistics, 1994.
CA Cancer J. Clin., 44: 7.
- ***Bracken, R.B. and Mackay, B. (Eds.) (1991):***
Carcinoma in situ.
In: Atlas of Bladder Pathology, Igaku-Shoin Medical
Publishers, Tokyo, p. 82.
- ***Buchumensky, V.; Klein, A.; Zemer, R.; Kessler, O.J.;
Zimlichman, S. and Nissenkorn, I. (1998):***
Cytokeratin 20: A new marker for early detection of bladder
cell carcinoma.
J. Urol., 160: 1971.
- ***Burchardt, M.; Burchardt, T.; Shabsight, A.; Taille, A.; Benson,
M.C.; and Sawczuk, I. (2000):***
Current concepts in biomarker technology for bladder
cancers.
Clin. Chem., 46: 595.

-
- **Canney, P.A.; Moore, M. and James, R.D. (1984):**
Ovarian cancer antigen CA 125: A prospective clinical assessment of its rule as a tumor marker.
Brit. J. Cancer, 50: 189.

 - **Carbin, B.; Ekman, P. and Gustafson, H. (1991):**
Grading of human urothelial carcinoma.
J. Urol., 145: 968.

 - **Carpinito, G.A.; Stadler, W.M. and Briggman, J.V. (1996):**
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract.
J. Urol., 156: 1280.

 - **Carroll, P.R. (1992):**
Urothelial carcinoma.
In: General Urology, Eds. Tanagho, E.A. and Mc Aninch, J.W., 13th ed., Appletones Lange, Norwalk, Connecticut, p. 341.

 - **Casella, R.; Huber, P.; Blochlinger, A.; Stoffel, F.; Dalquen, P.; Gasser, T. and Lehmann, K. (2000):**
Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: with 130 patients with biopsy confirmed tumor.
J. Urol., 164 (6): 1926.
-

- **Chan, D.W.; Beveridge, R.A. and Bruzek, D.J. (1988):**
Monitoring breast cancer with CA 549.
Clin. Chem., 34: 2000.

- **Chan, S.H.; Heng, S.S. and Oon, C.J. (1980):**
Comparison of various assays for detection of AFP in differentiating patients with primary hepatocellular carcinoma from control.
J. Clin. Pathol., 33: 722.

- **Chen, Y.-T.; Hayden, C.L.; Marchand, K.J. and Makuch, R.W. (1997):**
Comparison of urinary collection methods for evaluating urinary nuclear matrix protein, NMP22, as a tumor marker.
J. Urol., 158: 1899.

- **Claude, J.; Junze, E. and Rainer, F. (1986):**
Life-style and occupational risk factors in cancer of the lower urinary tract.
Am. J. Epid., 124: 578.

- **Coleman, W.D. and Tsongalis, G.J. (1996):**
Molecular Diagnostics for the Clinical Laboratory, Totowa, N.J., Human Press.

- ***Coombes, R.C.; Powles, J.J.; Gozet, J.C.; Ford, H.T.; Shoane, V.P.; Laurence, D.J.R. and Naville, A.M. (1987):***
Biochemical markers in human breast cancers.
Lancet, I: 132.

- ***Corey, M.J. and Kinders, R.J. (1998a):***
Factor H related proteins are unregulated in bladder cancer.
Proceedings of the American Association for Cancer
Research, 39: 263.

- ***Coulombe, P.A. (1993):***
The cellular and molecular biology of keratins: Beginning a
new era.
Curr. Opin. Cell. Biol., 5: 17.

- ***De Lange, T. (1994):***
Activation of telomerase in a human tumor.
Proc. Natl. Acad. Sci. USA, 91: 2882.

- ***Dressler, L.G. and Bartow, S.A. (1988):***
DNA flow cytometry in solid tumors, practical aspects and
clinical applications.
Semin. Diagn. Pathol., 6: 55.

- *Eissa, S.; Swellam, M.; Sadek, M.; Mourad, S.; El-Ahmady, O. and Khalifa, A. (2002):*
Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
J. Urol., 168: 465.

- *El-Bolkainy, M.N. (1983):*
The pathology of cancer of the bilharzial bladder.
In: Bladder Cancer, Ed. El-Sebai, I., Vol. I, CRC Press, Florida, p. 83.

- *El-Bolkainy, M.N. (2000):*
Cancer of urinary tract.
In: Topographic Pathology of Cancer, NCI Cairo University (ed), 2nd ed., p. 57.

- *El-Bolkainy, M.N. and Chu, E. (Eds.) (1981):*
Evaluation of cytological screening for detection of bilharzial bladder cancer.
In: Detection of Bladder Cancer Associated with Schistosomiasis, Al-Ahram Press, Cairo, p. 174.

- *El-Bolkainy, M.N. and Ghoneim, M.A. (1972):*
Carcinoma of the bilharzial bladder in Egypt, clinical and pathological features.
Brit. J. Urol., 44: 561.

- *El-Sebai, I. (1978):*
Cancer of bilharzial bladder.
Urol. Res., 6: 233.

- *El-Sebai, I. (1981):*
Carcinoma of the urinary bladder in Egypt: Current clinical experience.
In: Detection of Bladder Cancer Associated with Schistosomiasis, Eds. El-Bolkainy, M.N. and Chu, E., Al-Ahram Press, Cairo, p. 9.

- *El-Sebai, I. (Ed.) (1983):*
Epidemiology of bladder cancer.
In: Bladder Cancer, Vol. I, CRC Press, Florida, p. 17.

- *El-Sebai, I.; Sherif, M. and Mansour, M.A. (1974):*
Verrucous squamous carcinoma of bladder.
Urology, 4: 407.

- *Ewing, R.; Tate, G.M. and Hetherington, J.W. (1987):*
Urinary fibrin / fibrinogen degradation products in transitional cell carcinoma of the bladder.
Br. J. Urol., 59: 53.

- ***Fey, E.G. and Penman, S. (1988):***
Nuclear matrix proteins reflect cell type of origin in cultured human cells.
Proc. Natl. Acad. Sci., USA, 85: 121.
- ***Fishman, W.H.; Inglis, N.R.; Stolbach, L.L. and Krant, M.J. (1968):***
A serum alkaline phosphatase isoenzyme of human neoplastic cell origin.
Cancer Res., 28: 150.
- ***Foresman, W.H. and Messing, E.M. (1997):***
Bladder cancer: natural history, tumor markers and early detection strategies.
Semin. Surg. Oncol., 13: 299.
- ***Friedrich, M.G.; Hellstern, A.; Hautmann, S.H.; Graefen, M.; Conrad, S.; Huland, E. and Huland, H. (2002):***
Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: A comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.
J. Urol., 168: 470.
- ***Gentzenburg, R.H.; Konety, B.R. and Oeler, T.A. (1996):***
Bladder cancer-associated nuclear matrix proteins.
Cancer Res., 56: 1690.

- ***Giannopoulos, A.; Manousakas, T., Gounari, A.; Constantinides, C.; Papadopoulou, H.C. and Dimopoulos, C. (2001):***

Comparative evaluation of the diagnostic performance of the BTA STAT test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.

J. Urol., 166: 470.

- ***Glashan, R.W. (1989):***

Clinicopathological aspects of premalignant and malignant lesions of the bladder and the role of industrial screening in their detection.

In: Urological and Genital Cancer, Eds. Oliver, R.T. and Blandy, J.P., Blackwell Scientific Publications, Oxford, London, p. 77.

- ***Gold, P. and Freeman, S.O. (1965):***

Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques.

J. Exp. Med., 121: 439.

- ***Gonzalez, C.A.; Errezola, M. and Estrada, A. (1985):***

Occupation, tobacco use, coffee and bladder cancer in the country of Mataro.

Cancer, 55: 2031.

- ***Gonzalez-Zulueta, M.; Shibata, A. and Ohneseit, P.F. (1995):***
High frequency of chromosomal group allelic loss and ChKn suppressor gene alterations in squamous cell carcinoma of the bladder.
J. Natl. Cancer Inst., 1383.

- ***Hammersmith oncology group and imperial cancer research fund. (1984):***
Antibody guided irradiation of malignant lesions. Three cases illustrating a new method of treatment.
Lancet, I: 1441.

- ***Hantgan, R.R.; Simpson-Haidaris, P.J.; Francis, C.W. and Marder, V.J. (2001):***
Fibrinogen structure and physiology.
In: Hemostasis and Thrombosis Basic Principles and Clinical Practice, Colman, R.W.; Hirsh, J.; Marder, V.J.; Clowes, A.W. and George J.N. (eds), 4th ed., The Lippincott Williams & Wilkins Company, Philadelphia, 12: 203.

- ***Hartage, P.; Silverman, D. and Hoover, R. (1987):***
Changing cigarette habits and bladder cancer risks: A case-control study.
J. Natl. Cancer Inst., 18: 1119.

- **Heicappell, R.; Schostak, M.; Muller, M. and Muller, K. (2000):**
Evaluation of urinary bladder cancer antigen as a marker for
diagnosis of transitional cell carcinoma of urinary bladder.
Scand. J. Clin. Lab. Invest. 60(4): 275.

- **Henderson, L.O.; Marti, G.I. and Gaigalas, A. (1998):**
Terminology and nomenclature for standardization in
quantitative fluorescence cytometry.
Cytometry, 33: 97.

- **Heney, N.N. (1992):**
Natural history of superficial bladder cancer.
Prognostic Urol. Clin. North. Am., 19: 429.

- **Heney, N.M.; Ahmed, S. and Flanagan, M.J. (1983):**
Superficial bladder cancer: Progression and recurrence.
J. Urol., 130: 1083.

- **Hobarth, K.; Maier, U. and Marberger, M. (1992):**
Topical chemoprophylaxis of superficial bladder cancer by
mitomycin C and adjuvant hyaluronidase.
Eur. Urol. J., 21: 206.

- **Jewett, H.J. and Strong, G.H. (1946):**
Infiltrating carcinoma of bladder, relation of depth of penetration of bladder wall to incidence of local extension and metastases.
J. Urol., 55: 366.
- **Jones, W.B.; Lehr, M. and Lewis, J.L. (1973):**
R.I.A. of B-subunit of HCG monitor of chemotherapy in gestational trophoblastic neoplasm.
Surgical Forum., 18: 563.
- **Kamor, A.F.; Hartage, P. and Hoover, R.N. (1988):**
Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder.
Cancer Res., 48: 3852.
- **Karcher, R.E. and Nuttall, K.L. (1999):**
In: Tietz Textbook of Clinical Chemistry, Eds. Burtis, C.A. and Ashwood, E.R., 3rd ed., Philadelphia, W.B. Saunders, p. 150.
- **Keese, S.; Briggman, J.B.; Thill, G. and Wu, Y.J. (1996):**
Utilization of nuclear matrix proteins for cancer diagnosis.
In: Critical Review in Eukaryotic Gene Expression, Vol. 6, Ed. Gary Stein, p. 189.

-
- **Keesee, S.; Meneghini, M.D.; Szaro, R.P. and Wu, Y.J. (1994):**
Nuclear matrix proteins in human colon cancer.
Proc. Natl. Acad. Sci., 91: 1913.
 - **Khafagy, M.M.; El-Bolkainy, M.N. and Mansour, M. (1972):**
Carcinoma of the bilharzial urinary bladder.
Cancer, 30: 150.
 - **Khanuja, P.S.; Lehr, J.E.; Soule, H.D.; Gehani, S.K.; Noto, A.C.;
Chouahury, S.; Chen, R. and Pienta, K.J. (1993):**
Nuclear matrix proteins in normal and breast cancer cells.
Cancer Res., 53: 3394.
 - **Kissane, J.M. (1990):**
The urinary system.
In: Anderson's Pathology, Vol. I; C.V. Mosby Company, St.
Louise, Baltimore, P. 804.
 - **Klein, A.; Zemer, R. and Buchumensky, V. (1998):**
Expression of cytokeratin 20 in urinary cytology of patients
with bladder carcinoma.
Cancer, 82: 349.
 - **Kinder, R.; Jones, T. and Root, R. (1998):**
Complement facto H or a related protein is a marker for
transitional cell carcinoma of the bladder.
Clin. Can. Res., 4: 2511.
-

- **Knudson, W.; Biswas, C. and Toole, B.P. (1984):**
Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis.
Proc. Natl. Acad. Sci. USA, 81: 6767.
- **Knudson, W.; Biswas, C. and Li, X-Q (1989):**
The role and regulation of tumor associated hyaluronan.
In: The Biology of Hyaluronan. CIBA Foundation Symposium No. 143, Ed. J. Whelan, New York: John Wiley & Sons, p. 150.
- **Kricka, L.J. (1991):**
Chemiluminescent and bioluminescent techniques.
Clin. Chem., 37: 1472.
- **Lange, P.H. and Fraley, E.E. (1977):**
Serum alpha-fetoprotein and human chorionic gonadotrophin in the treatment of patients with testicular tumors.
Urol. Cl. Nor. Am., 4: 393.
- **Lee, M.-Y.; Tsou, M.-H.; Cheng, M.-H.; Chang, D.-S.; Yang, A.L.-Y. and Ko, J.-S. (2000):**
Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma.
World J. Urol., 18: 401.

- **Lee, K.-H. (2001):**
Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer.
Yonsei Med. J., 42: 14.
- **Lightner, D.J.; Ercole, C.J. and Lange, P.H. (1989):**
The value of serum PSA determination after radical prostatectomy.
J. Urol., 142: 720.
- **Lin, R.Y.; Argenta, P.A.; Sullivan, K.M.; Stern, R. and Adzick, N.S. (1995):**
Urinary hyaluronic acid is a Wilms' tumor marker.
J. Pediat. Surg., 30: 304.
- **Lin, R.Y.; Miyamoto, H.; Fujinami, K.; Uemura, H.; Hosaka, M.; Iwasaki, Y. and Kubota, Y. (1996):**
Telomerase activity in human bladder cancer.
Clim. Cancer Res., 2: 929.
- **Lippenen, P.K.; Esklinen, M.J. and Hanpasalo, H. (1993):**
Grading of superficial bladder cancer by quantitative mitotic frequency analysis.
J. Urol., 149: 36.

- **Lobez-Abente, G.; Gonzalez, C.A. and Emezole, M. (1991):**
Tobacco smoke inhalation pattern, tobacco type and bladder cancer in Spain.
Am. J. Epid., 134: 880.
- **Lokeshwar, V.B.; Lida, N. and Bourguignon, L.Y. (1996):**
Endothelial cell adhesion molecule GP116 is a new CD44 variant (Ex 14-v10) involved in mediating hyaluronic acid – induced functions.
J. Biol. Chem., 271: 853.
- **Lokeshwar, V.B.; Soloway, M.S. and Block, N.L. (1998):**
Secretion of bladder tumor-derived hyaluronidase activity by invasive bladder tumor cells.
Cancer Lett, 131: 21.
- **Lokeshwar, V.B. and Soloway, M.S. (2001):**
Current bladder tumor tests: Does their projected utility fulfill clinical necessity?
J. Urol., 165: 1067.
- **Marchia, V.; Mariano, A.; Cavalcanti, M.; Copp, A.; Cecere, C.; Fraicla, G.; Elia, S. and Ferrante, G. (1987):**
Tumor markers and lung cancer.
Int. J. Biol. Markers, 2(3): 151.

- ***Mackay, E.V.; Khoo, S.K. and Daunser, B. (1981):***
Tumor markers.
In: Gynecologic Oncology, Ed. Malcolm Coppleson.
- ***Marder, V.J. and Budzynski, A.Z. (1974):***
The structure of fibrinogen degradation products.
In: Progress in Hemostasis and Thrombosis, Ed. T.H. Speat,
N.Y., Grune and Stratton, p. 141.
- ***Marshall, V.F. (1952):***
The relation of the preoperative estimate to the pathologic
demonstration of the extent of the vesical neoplasms.
J. Urol., 68: 714.
- ***Melicow, M.M. (1952):***
Histological studies of vesical urothelium intervening
between gross neoplasms in total cystectomy.
J. Urol., 68: 261.
- ***Messing, E.M.; Young, T.B. and Hunt, V.B. (1995):***
Comparison of bladder cancer outcome in men undergoing
hematuria home screening versus those with standard
clinical presentations.
Urol., 45: 387.

- *Mian, Ch.; Lodde, M.; Haitel, A.; Vigl, E.E. and Pycha, A. (2000):*
Comparison of the monoclonal UBC – ELISA test and the
NMP22 ELISA test for the detection of urothelial cell
carcinoma of the bladder.
Urol., 55(2): 223.

- *Miller, T.E.; Beausang, L.A.; Winchell, L.F. and Lidgard, G.P.*
(1992):
Detection of nuclear matrix proteins in serum from cancer
patients.
Cancer Res., 52: 422.

- *Mokhtar, N. (1991):*
Cancer Pathology Registry 1985-1989, NCI, Cairo
University, P. 12.

- *Moll, R.; Lowe, A.; Laufer, J. and Franke, W.W. (1992):*
Cytokeratin 20 in human carcinomas: A new histodiagnostic
marker detected by monoclonal antibodies.
Amer. J. Pathol., 140: 427.

- *Mostofi, F.K. (1983):*
Pathomorphology of tumors of the urinary bladder.
In: Bladder Cancer, Vol. I, Ed. El-Sebai, I., CRC Press,
Florida, p. 75.

- **Mostofi, F.K. (1988):**
Dysplasia versus atypia versus carcinoma in situ of bladder.
In: Difficult Diagnosis in Urology, Ed. Mc Cullough, D.L.,
Churchill Livingstone, New York, London, p. 165.

- **Myers, R.E.; Sutherland, D.J. and Malkin, D.G. (1978):**
CEA and breast cancer.
Cancer, 42: 1520.

- **Nakayama, J.; Saito, M.; Nakamura, H.; Mastura, A. and
Ishikawa, F. (1997):**
TLP1: a gene encoding a protein component of mammalian
telomerase is a novel member of WD repeats family.
Cell, 88: 875.

- **Nakayasu, H. and Berezney, R. (1989):**
Mapping replicational sites in the eucaryotic cell nucleus.
J. Cell. Biol., 108: 1.

- **Neville, A.M. and Cooper, E.F. (1986):**
Biochemical monitoring of cancer.
Clin. Biochem., 13: 283.

- ***Newling, D.W. (1996):***
Preventing recurrence and progression in superficial bladder cancer.
Curr. Opin. Urol., 6: 272.

- ***Niloff, J.M.; Knapp, R.C. and Schaetzi, E.M. (1984):***
CA 125 levels in obstetric and gynecologic patients.
Obstet. Gynecol., 64: 703.

- ***Pardoll, D.M.; Vogelstein, B. and Coffey, D.S. (1980):***
A fixed site of DNA replication in eucaryotic cells.
Cell, 19: 527.

- ***Pariante, J.L.; Bordenave, L. and Michel, P. (1997):***
Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma.
L. Urol., 158: 338.

- ***Pauwels, R.P.; Schapers, R.F. and Smeets, W.G. (1988):***
Grading in superficial bladder cancer: Morphological criteria.
Brit. J. Urol., 61: 129.

-
- ***Pinkel, D.; Landegent, J.; Collins, C.; Fuscoe, J.; Sergraves, R.; Lucas, J. and Gray, J. (1991):***
Fluorescence in situ hybridization with human chromosome-specific libraries: Detection of trisomy 21 and translocation of chromosome 4.
Proc. Natl. Acad. Sci., USA, 85: 9138.

 - ***Pinto, M.; Bernstein, L. and Brogan, D. (1987):***
Immuno-radiometric assay of CA 125 in effusions, comparison with carcinoembryonic antigen.
Cancer, 59: 218.

 - ***Price, C.M.; Kanfer, E.J.; Colman, S.M. and Greaves, M.F. (1992):***
Simultaneous genotypic and immunophenotypic analysis of interphase cells using dual-color fluorescence: A demonstration of lineage involvement in polycythemia Vera.
Blood, 1033.

 - ***Ramakumar, S.; Bhuiyan, J. and Besse, J.A. (1999):***
Comparison of screening methods in the detection of bladder cancer.
J. Urol., 161: 388.

 - ***Rao, J.Y. ; Hemstreet, G.P. and Hurst, R.E. (1993):***
Alterations in phenotypic biochemical markers in bladder epithelium during tumorigenesis.
Proc. Natl. Acad. Sci., USA, 90 : 8287.
-

- **Reuter, V. and Melamed, M.R. (1989):**
The lower urinary tract.
In: Diagnostic Surgical Pathology, Ed. Sternberg, C.N.,
Raven Press, New York, p. 315.

- **Rhyo, M.S. (1995):**
Telomeres, telomerase and immortality.
J. Natl. Cancer Inst., 87: 884.

- **Riley, R.S. and Ross, W. (1993):**
Application of flowcytometry in genetics and molecular
biology.
In: Clinical Applications Of Flowcytometry, Eds. Riley,
R.S.; Makin, E.J.; Ross, W., New York-Tokyo, Igaku-Shoin,
p. 705.

- **Robertson, S.C. and Read, G. (1982):**
The value of L.D.H. as a non-specific tumor marker for
seminoma of testis.
Br. J. Cancer, 46: 994.

- **Rose, N.R.; Macario, E.D.; Folds, J.D.; Lane, C.H. and
Nakamura, R.M. (1997):**
Manual of laboratory clinical immunology.
American Society of Microbiology, Washington, D.C.

- *Ross, J.S.; Del Rosario, A.D.; Figge, H.L.; Sheehan, C.; Fisher, H.A. and Bui, H.X. (1995):*
E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder.
Hum. Path., 26: 940.
- *Roth, G.D. (1992):*
Bladder Cancer.
Post. Grad. Med., 21: 103.
- *Sanchez-Carbayo, M.; Herrero, E. and Megias, J. (1999):*
Initial evaluation of UBC as a tumor marker for transitional cell carcinoma of the bladder.
J. Urol., 161: 1110.
- *Sanchez-Carbayo, M.; Herrero, E. and Megias, J. (1999):*
Comparative sensitivity of urinary CYFRA 21-1, UBC, TPA and NMP 22 to detect bladder cancer.
J. Urol., 162: 1951.
- *Sanchez-Carbayo, M.; Urrutia, M.; Silva, J.M.; Romani, R.; Gonzalez De Buitraro, J.M. and Navajo, J.A. (2001):*
Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP 22 for evaluating symptomatic patients at risk for bladder cancer.
J. Urol., 165: 1472.

- **Schmetter, B.S.; Habicht, K.K. and Lamm, D.L. (1997):**
A multicenter trial evaluation of the fibrin / fibrinogen degradation products test for detection and monitoring of bladder cancer.
Cancer J. Urol., 158: 801.
- **Schroder, F.H.; Cooper, E.H. and Denis, L. (1988):**
TNM classification of genito-urinary tumors, 1987. Position of EORTC Genito-urinary Group.
Br. J. Urol., 62: 502.
- **Sæe, W.A. and Fuller, J.R. (1992):**
Staging of advanced bladder cancer.
Urol. Clin. Nor. Am., 19: 663.
- **Sell, S. (1991):**
Cancer markers.
In: Comprehensive Textbook of Oncology, 2nd ed., Vol. I.,
Eds. Moosa, A.R.; Schempf, S.C.; Robson, M.C.,
Baltimore, Williams & Wilkins, p. 225.
- **Sharfi, A.R.; El-Sir, S. and Beileil, O. (1992):**
Squamous cell carcinoma of the urinary bladder.
Brit. J. Urol., 69: 369.

- ***Sherif, M.S. and Ibrahim, A.S. (Eds.) (1987):***
Final report of the Cancer Registry for the Metropolitan Cairo Area, 1972-1987.
In the profile of cancer in Egypt, National Cancer Institute, Cairo, p. 87.
- ***Sidranasky, D.; Tokino, T. and Hamilton, S.R. (1992):***
Identification of ras oncogenes mutations in the stool of patients with curable colo-rectal tumors.
Science, 256: 102.
- ***Silverberg, E.; Boring, C. and Squires, T.S. (1990):***
Cancer statistics, 40: 9.
- ***Silverman, D.I.; Hartage, P. and Morrison, A.S. (1992):***
Epidemiology of bladder cancer.
Hematol. Oncol. Clin. Nor. Am., 6: 1.
- ***Silverman, D.I.; Levin, L.I. and Hoover, R.N. (1989):***
Occupational risks of bladder cancer in the United States.
Whitemen J. Natl. Cancer Inst., 81: 1472.
- ***Skeet, R.G. (1990):***
Epidemiology of urogenital tumors.
In: Scientific Foundations of Urology, 3rd ed., Eds. Chisholm, G.D. and Fair, W.R., Heinemann Medical Book, Oxford, p. 576.

- ***Soloway, M.S.; Briggman, J.V. and Carpinito, G.A. (1996):***
Use of a new tumor marker, urinary NMP 22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
J. Urol., 156: 363.
- ***Sorokin, J.J.; Sugarbaker, P.H. and Zamcheck, N. (1974):***
Serial CEA assay.
JAMA, 228.
- ***Stampfer, D.S., Carpinito, G. and Rodriguez, J. (1998):***
Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.
J. Urol., 159: 394.
- ***Steiber, P.; Schmeller, N. and Schambeck, C. (1996):***
Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer.
Anticancer Res., 16: 3793.
- ***Stein, J.P.; Grossfeld, G.D. and Ginsberg, D.A. (1998):***
Prognostic markers in bladder cancer: A contemporary view of the literature.
J. Urol., 160: 645.

- **Steinbeck, G. (1990):**
Some aspects on the epidemiology of urothelial cancer.
Scand. J. Urol. and Neph., 137: 7.
- **Stern, M.; Longaker, M.T.; Adzick, N.S. Harrison, M.R. and Stern, R. (1991):**
Hyaluronidase levels in urine from Wilms' tumor patients.
J. Natl. Cancer Inst., 83: 1569.
- **Sumi, Sh.; Arai, K.; Kitahara, S. and Yoshida, K-I. (2000):**
Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: Comparison to voided urine cytology in the detection of transitional carcinoma of the bladder.
Clin. Chem. Acta, 296: 111.
- **Suzuki, T.; Suzuki, Y. and Fujioka, T. (1999):**
Expression of catalytic subunit associated with telomerase gene in human urinary bladder cancer.
J. Urol., 162: 2217.
- **Takahashi, M.; Coyonda, K. and Aze, Y. (1992):**
The rat urinary bladder as a new target of Hetero cyclic amine carcinogenecity: Tumor indication by 3 aminol-1-methyl-5H-pyridol (4,3-bindole acetate).
Jpn. J. Cancer Res., 84: 852.

- **Takeichi, M. (1993):**
Cadherins in cancer, implications for invasion and metastasis.
Curr. Opin. Cell. Biol., 5: 806.
- **Thomas, I.; Etoh, T.; Stamenkovic, S.; Mihm, M.C. and Byers, H.P. (1993):**
Migration of human melanoma cells on hyaluronate is related to CD44 expression.
J. Invest. Dermatol.; 100: 115.
- **Thompson, I.M. and Fair, W.R. (1989):**
The epidemiology of bladder cancer.
AUA Update Series, 8:210.
- **Tsihlias, J. and Grossman, H.B. (2000):**
The utility of Fibrin / Fibrinogen Degradation Products in superficial bladder cancer.
Urol. Clin. North Am., 27: 39.
- **UICC (1978):**
TNM classification of Malignant Tumors, 3rd Ed.
International Union Against Cancer, Geneva.
- **UICC (1987):**
TNM classification of Malignant Tumors, 4th Ed.
International Union Against Cancer, Geneva.

- ***Van Dalen, A.; Favier, J. and Eastham, W.N. (1984):***
Preliminary observation with a new monoclonal antibody in ovarian carcinoma.
Tumor Diagnostic and Therapy, 5: 67.
- ***Van Nagell, J.R. (1983):***
Tumor markers in ovarian cancer.
In: Clinics in Obstetrics and Gynecology, Ed. Diasia, P.J.,
W.B. Saunders Company Ltd, London, p. 197.
- ***Varnavides, L.A.; Higgins, N.J. and Clark C.G. (1978):***
Carcinoembryonic antigen in mammary diseases, A clinical appraisal.
Clin. Oncol., 4: 329.
- ***Vineis, P.; Esteve, J. and Hartage, P. (1988):***
Effects of the timing and type of tobacco in cigarette-induced bladder cancer.
Cancer Res., 48: 1849.
- ***Vineis, P.; Martone, T. and Randone, D. (1995):***
Molecular epidemiology of bladder cancer: Known chemical causes of bladder cancer occupation and smoking.
Urol. Oncol., 1: 137.

- ***Vineis, P. and Simonto, L. (1991):***
Proportion of lung and bladder cancers in males resulting from occupation.
Arch. Environ. Health, 46: 6.

- ***Waldmann, T.A. and Herberman, R.B. (1982):***
Tumor markers in diagnosis and monitoring therapy.
In: Cancer Medicine, Chap. 15, Eds. Holland, J.F. and Frei, E., Publ., Lea and Febiger, USA.

- ***Walkes, T.P. and Torney, D.C. (1978):***
Biologic markers and breast cancer.
Seminars in Oncology, 5(4): 434.

- ***Web, J.N. (1990):***
Histopathology of bladder cancer.
In: Scientific Foundations of Urology, Ed. Chisholm, G.D. and Fair, W.R., 3rd ed., Heinemann Medical Books, Oxford, p. 549.

- ***Weinberg, R.A. (1991):***
Tumor suppressor genes.
Science, 254: 1138.

- *West, D.C. and Kumar, S. (1989):*
The effect of hyaluronate and its oligo-saccharides on endothelial cell proliferation and monolayer integrity.
Exp. Cell. Res., 183: 179.

- *Whittemore, W.F. and Marshall, V.F. (1956):*
Radical surgery for carcinoma of the urinary bladder.
Cancer, 9: 596.

- *Wiener, H.G.; Mian, C. and Haitel, A. (1998):*
Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
J. Urol., 159: 1876.

- *Wright, W.E.; Piatyszek, M.A.; Rainey, W.E.; Byrd, W. and Shay, J.W. (1996):*
Telomerase activity in human germ line and embryonic tissues and cells.
Dev. Genet., 18: 173.

- *Yang, C.H., Lambie, E.J. and Snyder, M. (1992):*
NuMA: an unusually long coiled-coil related protein in the mammalian nucleus.
J. Cell. Biol., 116: 1303.

- **Zarate, A. and Mac Gregor, C. (1982):**
B-subunit and the control of trophoblastic disease.
Semi. Oncol., 9: 187.
- **Zippe, C.; Pandragni, L. and Lakshmi, P. (1999):**
NMP22 is sensitive, cost effective test in patients at risk for
bladder cancer.
J. Urol., 161: 62.